 |
Does that MDS diagnosis need a second opinion? An interview with Mikkael Sekeres
A study has demonstrated that blood cancers known as myelodysplastic syndromes/neoplasms (MDS) are commonly misdiagnosed, putting patients at risk for treatment mistakes and other potentially harmful consequences. In this interview we provide you with a breakdown of key points of the research. |
Latest articles |
 |
AI detection software achieves 100% sensitivity rate for melanoma
Presented at this year’s European Academy of Dermatology and Venereology Congress (EADV; 11–14 October, Berlin, Germany), impressive results have emerged from a study using AI software to detect skin cancer. Read the full news piece on Future Medicine AI Hub. |
 |
Across Europe there are significant disparities in access to cancer care. Access to new medicines varies from 4 months to almost 2 years post-market authorization across countries and regions. In this opinion piece Gerwin Winter (BeiGene, Basel, Switzerland) and Eric Low (ELC, UK) discuss potential innovative solutions to address these disparities. |
 |
Looking to the future of immunotherapy in cancer treatment
Millions of people with cancer already benefit from immunotherapy, but there is always more we can do to develop transformative treatments. Find out about patient-focused solutions, such as immune-cell engagers and next-generation cell therapies in our latest opinion article. |
No comments:
Post a Comment